Edurant (rilpivirine) News

12 3 4 5 6 7 8 9 10 11 12 13...15 16 »

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabotegravir and Rilpivirine concentrations and HIV-1 RNA suppression in genital fluids and rectum in people with HIV on long-acting intramuscular Cabotegravir plus Rilpivirine antiretroviral therapy. (Pubmed Central) - Feb 18, 2026
P4
All participants maintained HIV-1 RNA <20 copies/mL in all matrices. Clinical Trial Registration: EudraCT Number: 2021-006779-41.

|||||||||| Edurant (rilpivirine) / J&J
Journal: A new strategy based on drug-linker-nanocarrier interactions to design new HIV-1 non-nucleoside reverse transcriptase inhibitors. (Pubmed Central) - Feb 16, 2026
This study focuses on harnessing the potential of Rilpivirine (RPV), a widely recognized non-nucleoside inhibitor, as a foundational structure for designing and synthesizing inhibitors with superior anti-HIV-1 activities compared to RPV...The innovative strategy employed in this research, focusing on drug-linker-nanocarrier interactions, introduces a promising avenue for designing and developing robust HIV-1 RT inhibitors with potential clinical applications. The findings emphasize the approach's potential for addressing challenges posed by drug-resistant mutations, opening new possibilities for advancing antiretroviral therapy.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Optimizing the patient journey: Insights from early implementation of long-acting cabotegravir and rilpivirine in four urban Ryan White-funded clinics in the United States. (Pubmed Central) - Feb 13, 2026
Optimizing the LAI-CAB/RPV patient journey requires developing a specialized support framework that is distinct from oral ART protocols. This new treatment modality requires a tailored approach that addresses unique challenges, including facilitating candid discussions about adherence contingencies, managing the physical and psychological aspects of injection experiences, ensuring meaningful and consistent provider relationships amid changing care patterns and providing enhanced support during treatment transitions.

||||||||||  Edurant (rilpivirine) / J&J
New P1/2 trial:   (EUDRACT) -  Feb 10, 2026
P1/2, N=155, ,  Sponsor: National Institute of Allergy and Infectious Diseases, Division of AIDS

|||||||||| Journal: Persistence on dolutegravir-containing two- and three-drug-regimens in clinical practice. (Pubmed Central) - Feb 9, 2026
However, the study's retrospective nature and center-specific characteristics may limit generalizability. More real-world data are warranted to confirm these results.

|||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
PK/PD data, Journal: Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine. (Pubmed Central) - Jan 23, 2026
Ventrogluteal administration is associated with more consistent pharmacokinetics and improved tolerability, supporting its use as the preferred site for long-acting CAB/RPV. Although CAB trough levels were modestly lower and occasionally fell below predefined thresholds with VG injection, this did not impact virologic outcomes, reinforcing its clinical suitability in most settings.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical, Journal, Real-world evidence: Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1. (Pubmed Central) - Jan 20, 2026
In this real-world study, CAB+RPV LA maintained high rates of virologic suppression, was well tolerated, and led to increased treatment satisfaction through 24?months following switch. These data reinforce the findings of the Phase 3/3b CAB+RPV LA program and support the continued use of CAB+RPV LA in routine clinical care.

|||||||||| Preclinical, Journal: Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model. (Pubmed Central) - Jan 16, 2026
We document protection in macaques by one-time CAB LA/RPV LA PEP under highly stringent modeling conditions. Delayed breakthrough infections highlight potential diagnostic challenges associated with this PEP modality and underscore the need for prolonged follow-up.

|||||||||| Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity. (Pubmed Central) - Jan 9, 2026
To improve the safety and selectivity of etravirine (ETR), cyclization strategy was employed by replacing the pyrimidine ring with a dihydropteridin-6(5H)-one scaffold affording a series of novel bicyclic tetrahydropteridine derivatives...Notably, 16a showed negligible cytotoxicity (CC50 = 196.46 ?M) and high selectivity index (SI = 65,789), greatly surpassing ETR (CC50 > 4.6 ?M, SI > 1436) and rilpivirine (RPV) (CC50 > 4.0 ?M, SI > 3989)...Additionally, 16a displayed minimal sensitivity to CYP enzymes, no inhibition of the hERG potassium channel, and no detectable acute toxicity at an in vivo dose of 2 g/kg. Collectively, these results highlight 16a as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.

|||||||||| Edurant (rilpivirine) / J&J
Journal: Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States: Findings from the antiretroviral pregnancy registry. (Pubmed Central) - Jan 2, 2026
Review of available data from the APR does not indicate an association between adverse pregnancy or birth outcomes and oral-RPV exposure, overall or by timing of exposure. Since APR targets primarily teratogenic effects, findings for non-teratogenic effects should be interpreted with caution.

|||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
PK/PD data, Journal: Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics. (Pubmed Central) - Dec 30, 2025
Since APR targets primarily teratogenic effects, findings for non-teratogenic effects should be interpreted with caution. These findings support ultrasound guidance as a practical approach to improve injection accuracy and patient comfort, particularly in individuals at higher risk of poor intramuscular deposition or prior tolerability issues.

|||||||||| remdesivir / Generic mfg., Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD)
Journal: Detailed in silico Evaluation of WNV Proteins: Dynamic and Thermodynamic Insights into Doravirine as a Potential Multitarget Agent. (Pubmed Central) - Dec 18, 2025
Triplicate MD simulations and residue-level fluctuation analyses further confirm doravirine's stability and consistent interaction patterns in all binding sites, highlighting its potential as a promising candidate for WNV inhibition with multitarget activity. These findings provide in silico evidence supporting doravirine as a promising multitarget inhibitor of WNV, warranting further investigation for its repurposing for WNV treatment.

|||||||||| Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
PK/PD data, Journal: Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible. (Pubmed Central) - Dec 12, 2025
Specifically, it focuses on intensive pharmacokinetic monitoring following deltoid administration of LAI rilpivirine and cabotegravir in a 29-year-old transgender woman with progressive multifocal leukoencephalopathy and swallowing difficulties...By day 10, the patient's clinical condition had deteriorated, leading to hospice care and subsequent death. Rilpivirine exposure after deltoid injection appeared lower than that typically reported after gluteal or thigh administration, although intracellular drug concentrations may differ from plasma levels, potentially mitigating clinical concerns.

|||||||||| P3 data, Journal: Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/ emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study. (Pubmed Central) - Nov 30, 2025
P3
Rilpivirine exposure after deltoid injection appeared lower than that typically reported after gluteal or thigh administration, although intracellular drug concentrations may differ from plasma levels, potentially mitigating clinical concerns. Cabotegravir

|||||||||| Edurant (rilpivirine) / J&J, Vemlidy (tenofovir alafenamide) / Gilead
PK/PD data, Journal: Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV. (Pubmed Central) - Nov 28, 2025
In our study, no significant effect of pregnancy on rilpivirine pharmacokinetic parameters was reported. No dose adjustment for orally-administered rilpivirine should be recommended in this setting.

|||||||||| Edurant (rilpivirine) / J&J
Journal: Sterile abscesses following administration of long-acting injectable rilpivirine for HIV. (Pubmed Central) - Nov 20, 2025
We describe a case of a young adult with sterile abscesses at the sites of two consecutive injections. This case describes a significant side effect noted during post-market roll-out.

|||||||||| Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD)
Journal: High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon. (Pubmed Central) - Nov 12, 2025
This case describes a significant side effect noted during post-market roll-out. The high level of resistance found in this study, coupled with the identification of DRMs either in circulating and archived viruses, only suggests that a comprehensive profiling of DRMs in both viral populations would provide additional information for adolescents with a detectable viremia.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
PK/PD data, Journal, Real-world evidence: Exploring the Interaction Between Injection Site and Biological Sex on the Real-world Population Pharmacokinetics of Long-acting Cabotegravir and Rilpivirine in People With HIV. (Pubmed Central) - Oct 27, 2025
Subcutaneous depot deposition after intramuscular injections is not uncommon, occurring more frequently in females and is associated with increased skin to muscle thickness. Slower absorption of cabotegravir from subcutaneous administration contributes to the observed sex differences in drug concentrations.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Necrotic skin reaction following the administration of intramuscular injections of long-acting cabotegravir/rilpivirine and alternatively-sourced testosterone. (Pubmed Central) - Sep 29, 2025
Slower absorption of cabotegravir from subcutaneous administration contributes to the observed sex differences in drug concentrations. After being reviewed in ambulatory care, the emergency department and an outpatient plastic surgery clinic settings over the course of 3

|||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, Real-world evidence: Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load. (Pubmed Central) - Sep 27, 2025
We present a case series of eight PWH treated at two tertiary centers in Italy, all of whom faced persistent viremia, adherence difficulties, malabsorption syndromes, or psychosocial barriers. Following the switch to CAB/RPV-LA, all patients, despite heterogeneous clinical profiles and baseline virological status, achieved and maintained virologic suppression, demonstrated improved adherence, and experienced no serious adverse events.

|||||||||| Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors. (Pubmed Central) - Sep 4, 2025
Additionally, A12 exhibited favorable oral bioavailability (F = 29.2%) and an extended elimination half-life (T 1/2 = 13.56 h), enabling convenient oral administration at minimal doses. These findings indicated that A12 could serve as a promising drug candidate for HIV treatment.

|||||||||| Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Review, Journal: Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review. (Pubmed Central) - Aug 28, 2025
Although real-world data are still emerging, they suggest similar trends, including a possible improvement in lipid profiles. Overall, LA CAB/RPV appears to be a safe, well-tolerated and effective treatment option, although longer-term follow-up is needed.

|||||||||| Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Intelence (etravirine) / J&J
Journal: Synthesis and biological evaluation of N-acyl diaryl pyrimidines (NDAPYs) as novel reverse transcriptase inhibitors. (Pubmed Central) - Aug 21, 2025
In this study, we designed novel molecules by the addition of a N-acyl group to the C4-position of Rilpivirine/Etravirine basic scaffold, a well-known class of DAPYs, in order to provide more interactions with K103 and E138 in Reverse Transcriptase. This was leading, as expected, to better in vitro RT inhibition, and the compounds 12c (56 %) and 12

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare
PK/PD data, Journal: Cabotegravir pharmacokinetics in Asian population with and without HIV. (Pubmed Central) - Aug 20, 2025
No dose adjustment is recommended for Asian populations with and without HIV. Cabotegravir pharmacokinetic data from any Asian country/region may guide pharmacokinetic evaluation and regulatory considerations across Asian regions.

|||||||||| Edurant (rilpivirine) / J&J
Clinical, P2 data, PK/PD data, Journal: Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study. (Pubmed Central) - Aug 19, 2025
P2
Rilpivirine in combination with background ART was well-tolerated and maintained virologic suppression from baseline through week 48 in the studied population of children living with HIV-1. Rilpivirine exposure was within the target range for all doses.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Biomarker, Journal: Cerebrospinal fluid concentrations, viral suppression and biomarkers with long-acting cabotegravir and rilpivirine intramuscular injections. (Pubmed Central) - Aug 10, 2025
The combination of LA CAB/RPV can achieve therapeutic CSF concentrations throughout the dosing intervals and may suppress HIV replication in the CNS. No significant changes in CSF biomarkers of inflammation or neuronal injury were observed, indicating a neutral CNS effect.

|||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Subcutaneous injections of cabotegravir + rilpivirine long-acting in virally suppressed adults with HIV-1. (Pubmed Central) - Aug 8, 2025
P3
No significant changes in CSF biomarkers of inflammation or neuronal injury were observed, indicating a neutral CNS effect. Pharmacokinetics and efficacy were similar between CAB+RPV LA SC and IM administration; however, due to the higher incidence and duration of ISRs, along with lower tolerability and acceptability of SC injections, SC administration with the current CAB LA and RPV LA formulations is not further being evaluated.

|||||||||| Edurant (rilpivirine) / J&J
Observational data, Retrospective data, Journal: Brief Report: Switching to Long-Acting CAB/RPV: Data From an Italian Monocentric Cohort. (Pubmed Central) - Aug 8, 2025
Pharmacokinetics and efficacy were similar between CAB+RPV LA SC and IM administration; however, due to the higher incidence and duration of ISRs, along with lower tolerability and acceptability of SC injections, SC administration with the current CAB LA and RPV LA formulations is not further being evaluated. Our findings showed that CAB/RPV LAI Q8W is tolerated well in clinical practice, with high adherence to the injection schedule and few discontinuations mainly related to injection site-related pain.

||||||||||  Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment change, Trial withdrawal, HEOR:  Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (clinicaltrials.gov) -  Jul 30, 2025
P4, N=0, Withdrawn,  Sponsor: Juan A. Arnaiz
Our findings showed that CAB/RPV LAI Q8W is tolerated well in clinical practice, with high adherence to the injection schedule and few discontinuations mainly related to injection site-related pain. N=150 --> 0 | Unknown status --> Withdrawn

|||||||||| Review, Journal: The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections. (Pubmed Central) - Jul 30, 2025
The long-acting CAB plus RPV should not be administered in patients treated with rifampicin or rifabutin, patients with virological failure or patients with resistance to CAB or RPV, or patients with hepatitis B virus (HBV) infection. Long-acting CAB+RPV may lead to pain at the site of injection which would diminish over time.

||||||||||  Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion:  More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) -  Jul 25, 2025
P1/2, N=168, Completed,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Long-acting CAB+RPV may lead to pain at the site of injection which would diminish over time. Active, not recruiting --> Completed

|||||||||| New trial: Research on the Psychological Status of Patients With HIV-1 Infection (clinicaltrials.gov) - Jul 25, 2025
P=N/A, N=500, Not yet recruiting, Sponsor: Shanxi Bethune Hospital

||||||||||  Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Trial completion:  MAFALDA-R: Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (clinicaltrials.gov) -  Jul 18, 2025
P4, N=63, Completed,  Sponsor: Fundacion SEIMC-GESIDA
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Journal, Real-world evidence: Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period. (Pubmed Central) - Jul 8, 2025
Active, not recruiting --> Completed This real-world study, with a 44-month observation period and follow-up of up to 10

|||||||||| Edurant (rilpivirine) / J&J
P2 data, PK/PD data, Journal: Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-na (Pubmed Central) - Jun 12, 2025
P2
This real-world study, with a 44-month observation period and follow-up of up to 10 At week 48, rilpivirine achieved adequate viral suppression in antiretroviral-na

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Journal: Perspectives of people with HIV on implementing long acting cabotegravir plus rilpivirine in clinics and community settings in the UK: results from the anti-sexist, anti-racist, anti-ageist ILANA study. (Pubmed Central) - Jun 4, 2025
P
Those that chose community delivery found it highly acceptable and feasible. Further exploration of CAB + RPV delivery in alternative community sites not offered (eg, primary care, pharmacies) is warranted.

||||||||||  Jiebeian (azvudine) / Genuine Biotech
New P1 trial:  A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV) (clinicaltrials.gov) -  Jun 3, 2025
P1, N=15, Completed,  Sponsor: Henan Genuine Biotech Co., Ltd.

|||||||||| Edurant (rilpivirine) / J&J
PK/PD data, Journal: Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles. (Pubmed Central) - May 30, 2025
We identified compounds 5i3 and 5e2, with robust antiviral efficacy against wild-type HIV-1 and rilpivirine-resistant strains...5i3 exhibited good pharmacokinetic properties and favorable safety profiles, without substantial cytochrome P450 inhibition, and excellent oral bioavailability. These derivatives represent a promising scaffold for the development of anti-HIV drugs.

|||||||||| Edurant (rilpivirine) / J&J
Journal: Rilpivirine Ionic Liquid Nanoemulsion Augments the Oral Bioavailability of Rilpivirine and Its Delivery to the HIV Sanctuary Sites. (Pubmed Central) - May 20, 2025
Furthermore, compared to the RPV suspension, both SNES formulations containing RPV-Doc resulted in significantly higher and sustained RPV levels in the HIV sanctuary sites such as mesenteric lymph nodes and the brain. Taken together, our innovative approach can be used to improve the oral bioavailability and tissue penetration of RPV, which can eventually result in a reduction in the pharmacokinetic variability and therapeutic dose of RPV leading to optimal drug utilization.

|||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Observational data, Journal: Eligibility for Intramuscular Cabotegravir/Rilpivirine in HIV-Positive Patients: An Observational Study. (Pubmed Central) - May 12, 2025
However, lack of adherence and the costs associated with intramuscular therapy represent barriers to its implementation. Strategies to improve adherence and cost-effectiveness studies are needed.

|||||||||| Edurant (rilpivirine) / J&J
Molecular sequence analysis reveals frequent A6 variant associated transmission of rilpivirine resistance and reflects cross-country transmission patterns () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1908;
In late diagnosed Ukrainian migrants the most commonly transmitted DRMs are ripivirine associated E138A/K/G substitutions. Phylogenetic tree analysis confirms the direction of majority of transmissions from Ukraine to Poland but after-migration within Poland transmissions were also revealed.

|||||||||| Comparative effectiveness of modern antiretroviral therapy regimens among people living with HIV in China: a multicenter cohort study () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_1345;
Most frequently used third ART drugs included nevirapine, efavirenz, dolutegravir, lopinavir, and others (including darunavir, raltegravie, elvitegravir and rilpivirine). Our findings further reinforce the positioning of dolutegravir-based regimens as preferred options in LMICs.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare
Pregnancy and neonatal outcomes following prenatal exposure to cabotegravir (CAB): data from The Antiretroviral Pregnancy Registry (APR) (MH2) - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_472;
Providers are encouraged to register ARV exposed pregnancies, especially those exposed to newer ARVs such as CAB, at APR (apregistry.com). ?

|||||||||| Reimbursement, US reimbursement, Journal, HEOR: Budget Impact of Eliminating Medicaid Prior Authorizations for Antiretrovirals in Washington State. (Pubmed Central) - May 9, 2025
Elimination of Medicaid PAs will result in substantial new costs. Changes in drug formulary policy should consider opportunity costs.

|||||||||| Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Clinical data, Journal, Real-world evidence: Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND). (Pubmed Central) - Apr 30, 2025
Proportions of participants reporting "always" or "often" experiencing challenges related to HIV-1 treatment (fear of disclosure, adherence anxiety, reminder of HIV-1 status, and feeling stigmatized) decreased from baseline to month 12. Month 12 results from the real-world BEYOND study support the effectiveness of CAB + RPV LA for maintenance of virologic suppression and as a preferred treatment option for people with HIV-1.

|||||||||| Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Intelence (etravirine) / J&J
Journal: HIV-1 cross-resistance to second-generation non-nucleoside reverse transcriptase inhibitors among individuals failing antiretroviral therapy in Cameroon: implications for the use of long-acting treatment regimens in low- and middle-income countries. (Pubmed Central) - Apr 29, 2025
Among patients failing treatment in Cameroon, there is a high-level of cross-resistance to 2ndGenNNRTI due to wide exposure to 1stGenNNRTI. Thus, in LMICs sharing similar programmatic features, the use of NNRTI-sparing regimens should be prioritized as a public health approach, while second-generation-NNRTI long-acting regimens should be guided by genotyping or for clients without previous exposure to NNRTIs.

|||||||||| Edurant (rilpivirine) / J&J
P1 data, PK/PD data, Journal: A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV. (Pubmed Central) - Apr 29, 2025
P1
Long-acting (LA) cabotegravir 200-mg/mL (CAB200) injections are approved for HIV-1 prevention and as a complete LA HIV-1 treatment regimen with rilpivirine...Although CAB400-D injections demonstrated acceptable safety/tolerability, faster absorption than CAB200 limited potential dosing intervals to monthly dosing. Alternative cabotegravir formulations with longer dosing intervals are under clinical evaluation.

||||||||||  Edurant (rilpivirine) / J&J
Trial completion date:  A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (clinicaltrials.gov) -  Apr 28, 2025
P2, N=48, Active, not recruiting,  Sponsor: Janssen Sciences Ireland UC
Alternative cabotegravir formulations with longer dosing intervals are under clinical evaluation. Trial completion date: Dec 2031 --> Jun 2027

|||||||||| Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
New challenges and molecular approaches to adipose damage associated with obesogenic medications () - Apr 21, 2025 - Abstract #ECO2025ECO_739;
Our studies show that DTG strongly alters adipocyte functionality, acting mainly at the mitochondrial level as well as on lipid and glucose metabolism. Finally, TSP1 serum levels in DTG-treated patients infected with HIV could represent a potential biomarker of adipose tissue dysfunction.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Impact of switching to long-acting injectable cabotegravir plus rilpivirine on rectal HIV-1 RNA shedding and implications for transmission risk. (Pubmed Central) - Apr 15, 2025
Rectal HIV-1 shedding is common during bimonthly intramuscular CAB/RPV treatment and is also observed with oral ART. Shedding was independent of concurrent plasma HIV-1 RNA and rectal RPV concentrations, and was associated with pre-ART viral load.



	Diseases Companies Products Productz Mechanisms of Action Sites